Madrigal Pharmaceuticals, INC. (MDGL) — 8-K Filings

All 8-K filings from Madrigal Pharmaceuticals, INC.. Browse 17 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (17)

Madrigal Pharmaceuticals Announces Director, Officer, and Compensation Changes — Dec 11, 2025 Risk: low
Madrigal Pharmaceuticals, Inc. announced on December 5, 2025, changes related to its board of directors and executive compensation. Specifically, the company re
Madrigal Pharmaceuticals Files 8-K — Jul 30, 2025 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on July 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details
Madrigal Pharmaceuticals Terminates Agreement, Enters New One — Jul 22, 2025 Risk: medium
Madrigal Pharmaceuticals, Inc. announced on July 17, 2025, the termination of a material definitive agreement. The company also entered into a new material defi
Madrigal Pharmaceuticals Files 8-K for Security Holder Vote — Jun 20, 2025 Risk: medium
Madrigal Pharmaceuticals, Inc. filed an 8-K on June 20, 2025, to report the submission of matters to a vote of its security holders. The filing does not disclos
Madrigal Pharma Appoints New Chief Medical Officer — Apr 17, 2025 Risk: medium
Madrigal Pharmaceuticals, Inc. announced on April 16, 2025, the appointment of Dr. Marc Walter as Chief Medical Officer. Dr. Walter previously served as Senior
Madrigal Pharma Appoints New Chief Medical Officer — Mar 11, 2025 Risk: low
Madrigal Pharmaceuticals, Inc. announced on March 9, 2025, the appointment of Dr. Aleksej Z. Mrvaljevic as Chief Medical Officer, effective March 11, 2025. Dr.
Madrigal Pharmaceuticals Files 8-K on Financials — Feb 26, 2025 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also includes finan
Madrigal Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, and including financial stateme
Madrigal Pharmaceuticals Files 8-K on Financials — Oct 31, 2024 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on October 31, 2024, reporting results of operations and financial condition. The filing also includes financial sta
Madrigal Pharmaceuticals Files 8-K on Financials — Aug 7, 2024 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting on its results of operations and financial condition. The filing details financial stat
Madrigal Pharmaceuticals Appoints New CMO, Elects Directors — Jun 27, 2024 Risk: low
Madrigal Pharmaceuticals, Inc. announced on June 25, 2024, the appointment of Dr. Elias J. Growe as Chief Medical Officer, effective immediately. Dr. Growe prev
Madrigal Pharmaceuticals Files 8-K — May 7, 2024 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, and including financial statements a
Madrigal Pharma Secures $500M Credit Facility — Apr 2, 2024 Risk: low
Madrigal Pharmaceuticals, Inc. announced on March 27, 2024, that it has entered into a new credit agreement with JPMorgan Chase Bank, N.A. This agreement provid
Madrigal Pharmaceuticals Enters Material Definitive Agreement — Mar 20, 2024 Risk: medium
Madrigal Pharmaceuticals, Inc. announced on March 18, 2024, that it entered into a Material Definitive Agreement. The filing does not disclose specific details
Madrigal Pharma Buys Gene Therapy Assets from Arrowhead — Mar 15, 2024 Risk: medium
Madrigal Pharmaceuticals, Inc. announced on March 14, 2024, that it has entered into a definitive agreement to acquire a portfolio of gene therapy programs from
Madrigal Pharma Files 8-K on Financial Condition — Feb 28, 2024 Risk: low
Madrigal Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing, under SEC File Num
Madrigal Pharma Updates Business Address in 8-K Filing — Jan 8, 2024
Madrigal Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to update its business address to Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Cons

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX